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Nifurtimox and benznidazole are the front-line drugs used to treat
Chagas disease, the most important parasitic infection in the
Americas. These agents function as prodrugs and must be activated
within the parasite to have trypanocidal effects. Despite>40 years
of research, the mechanism(s) of action and resistance have re-
mained elusive. Here, we report that in trypanosomes, both drugs
are activated by a NADH-dependent, mitochondrially localized,
bacterial-like, type I nitroreductase (NTR), and that down-
regulation of this explains how resistance may emerge. Loss of a
single copy of this gene in Trypanosoma cruzi, either through in
vitro drug selection or by targeted gene deletion, is sufficient to
cause significant cross-resistance to a wide range of nitrohetero-
cyclic drugs. In Trypanosoma brucei, loss of a single NTR allele
confers similar cross-resistance without affecting growth rate or
the ability to establish an infection. This potential for drug resis-
tance by a simple mechanism has important implications, because
nifurtimox is currently undergoing phase III clinical trials against
African trypanosomiasis.
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Trypanosoma cruzi
The protozoan parasitesTrypanosoma cruzi,Trypanosoma brucei,and Leishmania are the causative agents of Chagas disease,
African sleeping sickness, and leishmaniasis, respectively. Over 20
million people are infected by these pathogens, and 500 million
are at risk. Because there is no immediate prospect of vaccines,
chemotherapy is of importance. Nitroheterocyclic drugs such as
nifurtimox and benznidazole have been used for40 years against
Chagas disease. However, their use is problematic. They can have
side effects, and some strains are refractory to treatment, the basis
for which has yet to be elucidated (1). In addition, medication is
expensive with, for example, nifurtimox regimes requiring 10 mg
per kg of body weight in three or four doses per day over a 60- to
120-day period. Because of these problems, the recommended
course of treatment is often not completed, resulting in consider-
able scope for the development of resistance. Plans to extend the
use of nifurtimox in combinational therapies with eflornithine to
African sleeping sickness are being evaluated (2). This, in conjunc-
tion with reports that several new nitroheterocycles have trypano-
cidal activities with no/low toxicity, has led to a renewed interest in
the use of these compounds as antiparasitic agents (3, 4).
Nitroheterocyclic compounds are characterized by a nitrogroup
linked to an aromatic ring (5). They include the broad-spectrum
nitrofuran and nitroimidazole antibiotics, which are effective
against a variety of bacterial and parasitic infections (5, 6). These
agents function as prodrugs and must undergo enzyme-mediated
activation within the pathogen to have cytotoxic effects, reactions,
which are catalyzed by nitroreductases (NTRs). Based on oxygen
sensitivity, NTRs are divided into two groups (7). Type I NTRs are
oxygen-insensitive, contain FMN as a cofactor, and function via a
series of two-electron reductions of the conserved nitro-group,
leading to moieties that promote DNA damage (8, 9). This class of
NTR is characteristically bacterial. The only trypanosomal enzyme
shown tomediate this type of activity is prostaglandin F2 synthase
(also known as ‘‘old yellow enzyme’’) (10, 11), although only under
anaerobic conditions. Type II NTRs are ubiquitous oxygen-
sensitive FAD- or FMN-containing enzymes that mediate a one-
electron reduction of the nitro-group generating an unstable nitro-
radical. In the presence of oxygen, this radical undergoes futile
cycling to produce superoxide, with the subsequent regeneration of
the parent nitro-compound (12, 13). In trypanosomes, type II
activity has been proposed as the main activation mechanism (14,
15). However, the only direct link between drug-induced reactive
oxygen species formation and trypanocidal activity stems from
functional studies on the iron-dependent superoxide dismutase
SODB1. Parasites lacking this gene aremore sensitive to nifurtimox
and benznidazole (16). Analysis of other components of the oxi-
dative defense system indicates they do not play a major role in
protecting trypanosomes against nitroheterocyclic drugs (17–22).
To resolve how nitroheterocyclic drugs are activated by trypano-
somes, we used two approaches: the first involved in vitro selection
to generate nifurtimox-resistant parasites, and the second entailed
functional analysis of a recently identified trypanosomal type I
NTR. Here, we demonstrate that this type I NTR has the capacity
to metabolize a wide range of nitroheterocyclic drugs, and that a
reduction in this activity in both T. cruzi and T. brucei confers
resistance to these trypanocidal agents.
Results
Selection of Nifurtimox-Resistant T. cruzi. To investigate the mech-
anism of nifurtimox resistance, we cultured T. cruzi in the presence
of 10 M nifurtimox for 8 months (Materials and Methods). This
drug concentration inhibits parasite growth by 99%. Several
drug-resistant parasite populations were generated independently.,
and these were cloned by limited dilution (designated NifR). We
first investigated the growth properties of three NifR clones (Fig.
1A). In the absence of nifurtimox, their doubling time was compa-
rable to the parental line. When NifR parasites were grown in
medium containing nifurtimox (10 ), the doubling time in-
creased 2-fold; by comparison, there was no growth in the parental
line beyond 1 week. We next determined the extent of nifurtimox
resistance by establishing the IC50. All clones were 4-fold more
resistant to nifurtimox than controls (Fig. 1B). When the studies
were expanded to include other nitroheterocyclic drugs, cross-
resistance was observed to benznidazole, megazol, and nitrofura-
zone (Fig. 1B). The phenotype was specific to this class of com-
pound, because NifR clones had the same sensitivity to the
nonnitro-compound rimantadine as the parental line.
In vitro drug selection has been shown to give rise to parasites
with an altered karyotype (11, 23). To investigate whether this had
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occurred here, we analyzed the chromosomal profiles fromparental
and NifR parasites and found that an 800-kbp band present in
parental cells was missing from NifR clones (Fig. 1C). This corre-
lated with a reduction in nifurtimox reducing activity in NifR
parasites comparedwith that of controls (2.79 0.20 vs. 6.73 1.18
nmol NADH oxidized min 1mg1 protein). Because nifurtimox
and benznidazole are prodrugs, we postulated that the observed
resistance might result from a reduction in the copy number of the
gene encoding the physiological activator, and that it could be
present on this chromosome. Intriguingly, in the parental T. cruzi
line, a putative type I NTR gene is located on chromosome
homologues of 1,000 and 800 kbp (Fig. 1D).
Trypanosomes Express a Functional Type I NTR. Type I NTRs are a
family of bacterial FMN-containing oxidoreductases, many of
unknown function (24). There is a single type I NTR-like gene in
both T. cruzi (TcNTR; GenBank accession no. XP810645) and T.
brucei (TbNTR; GenBank accession no. XP846343). Both en-
zymes contain a predicted N-terminal mitochondrial-targeting sig-
nal and a nitroreductase domain with several residues that may
interact with FMN (25) (supporting information (SI) Fig. S1). To
investigate whether TcNTR could function as an oxidoreductase,
the catalytic domain was expressed as a recombinant protein in
bacteria. During purification, fractions containing the recombinant
enzyme were yellow, suggestive of a flavoprotein. TcNTR activity
was then assessed in the presence of various nitroaromatic com-
pounds (Fig. 2A). This demonstrated that the enzyme could me-
tabolize a range of nitroheterocycles including nitrofurans (such as
nifurtimox, nitrofurantoin, and nitrofurazone) and nitroimidazoles
(such as benznidzazole andmegazol) usingNADHas reductant; no
activity was observed when NADPH was used as electron donor
(Fig. 2B). A Hanes plot revealed a linear relationship from which
the apparent Km for nifurtimox was determined (0.35  0.08 M)
(Fig. 2C). Further analysis gave an apparent Vmax value of 496 13
nmol NADH oxidized min1mg1 with a catalytic specificity
(Kcat/Km) of 7.1 105 (Fig. 2D). These data confirmed that TcNTR
could function as a NADH-dependent nitroreductase and could
reduce several trypanocidal agents.
TcNTRNull Mutants Are Cross-Resistant to Nitroheterocyclic Drugs.To
assess whether the drug-resistance phenotype observed inNifR cells
was specifically due to a reduction in the NTR copy number, we
insertionally inactivated one TcNTR gene in the T. cruzi genome
(Fig. S2). DNA fragments corresponding to the 5 and 3 regions of
TcNTR were amplified and cloned sequentially on either side of a
cassette containing a puromycin resistance marker. The construct
was then used to transform T. cruzi epimastigotes and clones
selected using puromycin. Southern hybridization of genomic DNA
fromheterozygous parasites (TcNTR/) showed that oneTcNTR
allele could be disrupted (Fig. S2), with no obvious effect on
parasite growth (Fig. 3A). To evaluate whether a reduction in the
TcNTR copy number affected resistance to nitroheterocyclic drugs,
TcNTR/ parasites were grown in the presence of nifurtimox and
the IC50 determined (Fig. 3B). Heterozygotes were 2.5-fold more
resistant compared with controls. A similar level of cross-resistance
was observed when these studies were expanded to include nitro-
furazone and megazol (Fig. 3B). Interestingly, when the growth
inhibitory property of benznidazole was examined, the heterozy-
gous cell lines exhibited a higher level of resistance (5-fold)
(Fig. 3B).
To determine the importance of TcNTR to T. cruzi and examine
the full extent of nitroheterocyclic drug resistance due to inactiva-
tion of the corresponding gene, TcNTR/ cells were transformed
with a blasticidin knockout construct (Fig. S2). Southern hybrid-
ization of genomic DNA from recombinant parasite clones showed
that in T. cruzi epimastigotes, both alleles could be disrupted to
generate a TcNTR null mutant line (TcNTR/) (Fig. S2). To
evaluate whether inactivation of both copies of TcNTR resulted in
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Fig. 1. Nifurtimox-resistant T. cruzi obtained by in vitro culture are cross-resistant to other nitroheterocyclic drugs and have lost a copy of a TcNTR-containing
chromosome. (A) Cumulative cell density of parental (X10/6) and laboratory-generated nifurtimox-resistant (NifR) lines in medium containing 10M nifurtimox.
Two other NifR clones analyzed in parallel displayed similar growth properties. (B) The drug concentrations that inhibited T. cruzi growth by 50% were
established. The data are means from three experiments standard deviation (SD). Differences observed in susceptibility were statistically significant (P 0.01),
as assessed by Student’s t test. Rimantadine was used as a drug control. (C) Ethidium bromide-stained CHEFE gel containing genomic DNA from T. cruzi. The
asterisk (*) identifies an 800-kbp chromosome present in X10/6 (lane 1), but missing in NifR clones (lane 2). M corresponds to yeast DNA markers. (D)
Autoradiograph of T. cruzi chromosomal DNA separated by CHEFE and hybridized with TcNTR gene probe (lane order as in B).
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an increased resistance to nitrofurans and nitroimidazoles, Tc-
NTR/ cells were grown in the presence of the nitroheterocycles
(Fig. 3B). When exposed to nifurtimox, nitrofurazone, and mega-
zol, the null-mutant lines were 4-fold more resistant than controls,
whereas with benznidazole, the TcNTR/ cells exhibited an even
higher level of resistance (10-fold) (Fig. 3B). Thus, the sequential
depletion of TcNTR is accompanied by a stepwise increase in
resistance to a range of nitroheterocyclic drugs.
In contrast to heterozygous cells, TcNTR null mutants displayed
a growth defect having a doubling time twice that of controls (Fig.
3A). Additionally, the maximal cell density attained with these
cultures was consistently 4- to 5-fold lower (1  107 ml1 for
TcNTR/ compared with 5  107 ml1 for controls), and we
could detect no development of the needle-shaped infective try-
pomastigotes, with the stumpy epimastigotes generally having re-
duced motility. The inability of TcNTR/ to differentiate was
borne out by infection studies; unlike parental and heterozygous
lines, TcNTR null mutant parasites could not infect cultured Vero
cells. This indicates that TcNTR is essential for differentiation of
noninfectious T. cruzi epimastigotes into metacyclic trypomastig-
otes, the stage of the life cycle infective to humans.
Functional Analysis of TbNTR in Bloodstream Form T. brucei. Nitro-
heterocyclic compounds have shown promise in the treatment of
African sleeping sickness, with a nifurtimox/eflornithine combina-
tion demonstrating significant potential in phase III clinical trials
(2). To determine whether NTR plays a role in resistance toward
nitroheterocycles in T. brucei, we deleted one copy of TbNTR from
the genome of bloodstream form (BSF) parasites. DNA fragments
corresponding to the 5 and 3 flanks of TbNTRwere amplified and
cloned sequentially on either side of a cassette containing blastici-
din or puromycin resistance markers (Fig. S3). The constructs were
used to transform BSF T. brucei and clones selected. Southern
hybridization confirmed that one TbNTR allele could be deleted
from the genome, with either drug resistance cassette, generating
heterozygous parasites (TbNTR/PAC orTbNTR/BLA) (Fig.
S3). This had no effect on growth or the ability to generate a lethal
infection inmice (data not shown). To evaluate whether deletion of
one copy of TbNTR altered sensitivity to nitroheterocyclic drugs,
heterozygous cell lines were grown in the presence of nifurtimox
and the IC50 determined (Fig. 4A). Cells containing a single NTR
replacement were 3-fold more resistant than controls. When these
studies were expanded to include other nitroheterocyclic drugs, a
similar level of cross-resistance was observed to benznidazole,
megazol and nitrofurazone (Fig. 4A). This phenotype was specific
to nitroheterocycles, because heterozygous cells had the same
sensitivity to melarsoprol as the parental line.
If activation of nitroheterocycles by NTR is a major determinant
of trypanocidal activity, and deletion of the corresponding gene
gives rise to drug resistance, it is implicit that overexpression result
in hypersensitivity. TbNTR was cloned in-frame with the 9E10
epitope from the human c-myc protein in a vector that facilitated
tetracycline-inducible gene expression (26). The construct was used
to transformaT. bruceiBSF line, generating parasite clones capable
of overexpressing TbNTR (designated TbNTRRV). To demonstrate
that inducible expression was occurring, extracts from cells treated
with tetracycline (1 gml1) for 24 h were examined on Western
blots by using amonoclonal antibody against the 9E10 epitope (Fig.
S3). Lysates derived from parasites expressing tagged TbNTR
contained a band of the expected size (	35 kDa). We then
examined whether elevated levels of TbNTR affected sensitivity to
nitroheterocyclic compounds. T. brucei cells with an elevated level
of TbNTR (TbNTRRV  tetracycline) were shown to be 10-fold
more sensitive to all nitroaromatic drugs than controls (Fig. 4B).
This phenotype was shown to be specific to nitroheterocycles as
cells overexpressing TbNTR had the same sensitivity as controls to
melarsporol (Fig. 4B).
As shown, one TbNTR allele could be readily deleted from BSF
parasites. Attempts (16 independent transformations) to generate
a TbNTR double-knockout failed, leading us to speculate that the
protein is essential. To investigate this further, we deleted both
copies of the nitroreductase in TbNTRRV cells. When deleting the
second copy of the gene, tetracycline was added to the growth
medium every 3 days to ensure expression of the gene from the
‘‘rescue’’ locus. In the presence of tetracycline, both endogenous
copies of TbNTR could be deleted to generate a conditional
null-mutant cell line (TbNTRRV/) (Fig. S3). To determine
whether TbNTR is essential for BSF growth, the effect of with-
drawing tetracycline from the growth medium was examined (Fig.
4C). Under these conditions, three independent clones stopped
dividing after 3 days, whereas parasites cultured in the presence of
tetracycline grew at the same rate as controls. This clearly demon-
strated that in the infective stage, TbNTR is essential for growth.
NTR Is Targeted to the Mitochondrion in T. brucei. To investigate
whether NTR is mitochondrial, the 5 end of TbNTR was amplified
and ligated in-frame and upstream of the gene encoding the
enhanced GFP. The cloning was performed in a vector that
facilitated tetracycline inducible gene expression (26). The resultant
Fig. 2. Biochemical properties of TcNTR. (A) Postulated scheme for the
reduction of nitroheterocyclic compounds by NTRs; ‘‘red’’ represents the
reduced form of drug, whereas ‘‘oxid’’ represents the oxidized form. (B) TcNTR
activity was monitored by following the oxidation of NADPH or NADH (100
M) in the presence of TcNTR (0.2 g) and nifurtimox (100 M). (C) TcNTR
activity was monitored after the oxidation of NADH (100 M) in the presence
of TcNTR (0.2 g) and nifurtimox (0.5–100 M). All reactions were initiated by
the addition of the recombinant enzyme. TcNTR activities are expressed as
nanomolar NADH oxidized min1mg1 of enzyme. (D) TcNTR metabolizes a
range of nitroheterocyclic compounds.
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construct was used to transform BSF T. brucei and parasite clones
selected. To induce expression, cells were incubated in the presence
of tetracycline for 24 h, then fixed and examined by confocal
microscopy. For parasites expressing TbNTR-GFP, fluorescence
was restricted to a network that spread throughout the cell, a
pattern reported for trypanosomal proteins localized to the large
single mitochondrion (Fig. 5). To confirm this, cells were costained
with the mitochondrial dye, MitoTracker. When the images were
Fig. 3. Phenotypic effect of delet-
ing NTR from the T. cruzi genome.
(A) T. cruzi null mutants have a
growth defect. Mean cell density
was determined from three inde-
pendent epimastigote cultures. Tc-
NTR/ and TcNTR/ represent
the TcNTR heterozygous and null-
mutant cell lines, respectively. (B)
Growth inhibitory effect of nitro-
heterocyclic drugs on NTR-deficient
T. cruzi epimastigotes. Data are
means from four experiments SD,
and the differences in susceptibility
were statistically significant (P 
0.01), as assessed by Student’s t test.
G418 was used as a drug control.
Fig. 4. Phenotypic effect of altering the TbNTR copy
number in T.brucei. (A) Deletion of one copy of TbNTR
confers cross-resistance on T. brucei as judged by IC50.
(B) Overexpression of TbNTR (TbNTRRV) confers hyper-
sensitivity to nitroheterocyclic drugs. Data in A and B
are means from four experiments  SD, and the dif-
ferences in susceptibility were statistically significant
(P 0.01), as assessed by Student’s t test. Melarsoprol
was used as a drug control. (C) Cumulative cell density
of T. brucei BSF cells grown in the absence or presence
of tetracycline. Two other TbNTRRV/ clones ana-
lyzed in parallel displayed similar growth properties.
On the fifth and subsequent days, we observed an
outgrowth of viable parasites. This type of reversion is
frequently observed in T. brucei (21).
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superimposed, the pattern of colocalization indicated that TbNTR-
GFP was located in the same compartment as MitoTracker.
Discussion
This article describes the first instance of a type I NTR from a
eukaryotic organism and demonstrates that in trypanosomes, a
reduction in the level of its activity plays a major role in resistance
to nitroheterocyclic drugs. We also show that this mitochondrially
targeted protein is essential for establishing infections in the
mammalian host for both T. cruzi, an intracellular parasite, and T.
brucei, a bloodstream parasite.
Drug resistance is a major problem associated with a number of
infections. This occurs by a number of different mechanisms that
can broadly be divided into two groups: those that affect the drug
(such as reduced uptake, detoxification, or sequestration) or those
that impinge on the drug target (such as target modification or
amplification). Nitroheterocyclic compounds are prodrugs and
therefore require activation to mediate cytotoxic activity. There-
fore, factors that reduce/prevent this process can lead to resistance.
In bacteria, a link between resistance to nitrobased drugs and
activation was established35 years ago after the observation that
nitrofuran resistant Escherichia coli had reduced NTR activity, a
phenotype later shown to be due to the acquisition of mutations in
their type I NTR complement (8, 27). This mechanism has been
largely overlooked for the trypanocidal agents nifurtimox and
benznidazole, because type I NTR activity was believed to be
specific to bacteria. Instead, it was proposed that in trypanosomes,
these drugsmediate parasite killing by inducing oxidative stress (12,
14, 15). This hypothesis gained credence as trypanosomes were
reported to have a limited ability to metabolize reactive oxygen
species (28). However, it is now clear that trypanosomes possess an
array of enzyme-mediate antioxidant defense pathways, often
distinct from those in the host (17–22, 29). To investigate whether
trypanosomes possess a type I NTR and have potential to activate
nitroheterocycles by a bacterial-like mechanism, we used an E.
coli-type I NTR sequence to screen the T. cruzi and T. brucei
genome databases and identified a single hit in both cases. Initial
studies using the T. cruzi recombinant enzyme demonstrated it
could metabolize a range of nitrofuran and nitroimidazole drugs,
with no specific substrate preference. Therefore, in vitro, this NTR
has the potential to mediate the activation step (Fig. 2). To
conclusively demonstrate this, we generated T. cruzi and T. brucei
lines with reduced or elevated levels of enzyme. If NTR has a role
in drug activation, we predicted that reduction in NTR levels would
be associated with resistance to nitroheterocyclic compounds,
whereas overexpression would result in hypersensitivity. This is
what we observed (Figs. 3 and 4): nifurtimox and benznidazole are
activated in trypanosomes by a type I NTR, and reduced expression
results in drug resistance.
In parallel, we performed in vitro selection. By continuous
culturing of T. cruzi epimastigotes in the presence of nifurtimox, we
generated parasite cell lines that displayed cross-resistance to a
variety nitroheterocyclic compounds (Fig. 1). This has worrying
implications, because in a clinical context, nifurtimox and benznida-
zole need to be administered for several months, and inmany cases,
the treatment is not completed. This suggests considerable scope
for the development of drug resistance in the field. Indeed, strains
refractory to treatment are common, with 20–25% of cases being
resistant to nifurtimox and/or benznidazole (1, 30).
The endogenous function of NTR is essential to invasive try-
panosomes; TbNTR could not be deleted from BSF T. brucei, and
TcNTR-null mutants displayed an inability to differentiate to in-
fectious metacyclic trypomastigotes and could not infect mamma-
lian cells. Therefore, it is implicit thatNTRactivity in trypanosomes
is required to establish andmaintain infection.Although the precise
biological function of the trypanosomal NTRs remains unknown,
they are similar to NADH dehydrogenases, enzymes that catalyze
the transfer of electrons from NADH to ubiquinone-generating
ubiquinol (QH2) (31). In trypanosomes, several distinct NADH
dehydrogenases activities have been reported, including respiratory
chain complex I, a 33-kDa FMN-containing protein and a 54-kDa
FAD-containing protein (32–34). These activities have been ob-
served specifically in the insect form of T. brucei. In the BSF,
ubiquinone reduction is reported to only occur via mitochondrial
glycerol-3 phosphate dehydrogenase activity (35), because this
life-cycle stage does not possess a functionally intact respiratory
chain. Instead, they utilize an alternative electron sink, the trypano-
some alternative oxidase (TAO), to maintain redox balance within
the cell (36). TAO mediates electron transfer from QH2 to reduce
oxygen-generating water. In most organisms, ubiquinone is an
integral component of the respiratory chain, and QH2 functions as
an antioxidant either directly by inhibiting protein and lipid oxida-
tion in cell membranes or indirectly by transferring reducing
equivalents to vitamin E (37). The type I NTRs identified here may
correspond to a previously reported 33-kDa FMN-containing
NADH dehydrogenase activity or could represent an additional
class of ubiquinone-reducing enzyme whose activity is essential in
mammalian stage trypanosomes.
Our data identify a major mechanism that results in activation of
nitroheterocyclic drugs in trypanosomes. This has important im-
plications for drug policy and could account for the high levels of
T. cruzi infections, which are refractory to current drug regimes.
However, as we have shown, NTR is essential in BSF T. brucei and
for differentiation ofT. cruzi. Therefore, selective pressure to retain
some type I NTR activity appears to restrict drug resistance to an
upper limit of	5-fold. At this stage, though, we cannot exclude the
possibility that specific mutations in NTR could generate versions
of the enzyme that maintain the endogenous function but lose the
drug-activating capacity, thus resulting in even higher levels of drug
resistance. This is a scenario that will require close surveillance at
the level of both the laboratory and the field. One way forward,
suggested by our data, would be to develop drugs targeted at NTR.
Fig. 5. Localization of TbNTR in blood-
stream-form T. brucei. Parasites expressing
TbNTR-GFP (green) were costained with
DAPI (DNA; blue) and MitoTracker (mito-
chondrion; red). The cells were examined
by confocal microscopy. The pattern of co-
localization (yellow) is shown in the
merged image. (A) Expression of TbNTR-
GFP in a population of cells. (B) Single cell at
higher resolution.
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A dual therapy could then be used: initial treatment that relies on
prodrug activation by parasite type I NTR, and if this fails, the
targeting of the NTR activity itself.
Materials and Methods
Parasites. T. cruzi epimastigotes (clone MHOM/BR/78/Sylvio- X10/6) were grown
asdescribed(38).TransformedT.cruziweremaintainedinthesamemediumwith
5 g ml1 puromycin and/or 10 g ml1 blasticidin. T. cruzi amastigotes were
obtained from African green monkey kidney (Vero) cells infected with metacyclic
trypomastigotes. BSF T. brucei (Lister 427; clone 221a) were grown in HMI-11
medium(39).TransformedT.bruceiweremaintainedinmediumwith2.5gml1
blasticidin, 2 g ml1 puromycin, or 2.5 g ml1 hygromycin. T. brucei BSF lines
(2T1) that constitutively express the tetracycline repressor protein (26) were
grown in medium containing 1 g ml1 phleomycin. Tetracycline free FCS (Au-
togen Bioclear) was used in the media. Genomic DNA was isolated by using the
phenol/chloroform method, and intact trypanosomal chromosomes for contour
clamped homogenous field electrophoresis (CHEFE) analysis were extracted by
using an agarose-embedding technique (40) and separated by using a BioRad
CHEFE mapper.
Biochemical Properties. T. cruzi NTR was amplified from genomic DNA, the
fragment digested with BamHI/HindIII then cloned into the corresponding sites
of pTrcHis-C. E. coli BL-21, transformed with the plasmid pTrcHis-TcNTR, were
grown in NZCYM broth containing 50g ml1 ampicillin and protein expression
induced by IPTG. His-tagged TcNTR was affinity purified on a Ni-NTA column
(Qiagen). Cell lysis, column wash and elution steps were carried out in the
presence of protease inhibitors (Roche). Fractions were analyzed by SDS/PAGE
and protein concentrations determined by BCA protein assay system (Pierce).
TcNTRactivitywasmeasuredbyfollowingthechange inabsorbanceat340nm
because of NADH oxidation (41). A reaction mixture (1 ml) containing 50 mM
TrisCl, pH 7.0, 100 M NADH and nitroheterocycle was incubated at 22°C for 5
min. The background rate of NADH oxidation was determined and the reaction
initiated by addition of 0.2 g of TcNTR. As control, activity of any potentially
copurified E. coli proteins was also examined. Enzyme activity was calculated by
using  of 6,220 M1cm1. Data were analyzed by fitting to a rectangular
hyperbola (Kinenort program, A. G. Clark, University of Wellington, Welling-
ton, U.K.).
Construction of Trypanosomal Vectors and Parasite Transformation. The vectors
used to delete TcNTR or TbNTRwere generated as follows. For TcNTR knockout,
primers were designed to amplify 435- or 410-bp fragments from the 5 and 3
regions of the gene, respectively. These were cloned sequentially either side of a
puromycin (PAC) or blasticidin (BLA) resistance cassette. The constructs were
linearized (SacI/KpnI for the PAC vector or SacII/KpnI for the BLA vector) then
electroporated into T. cruzi epimastigotes (42). For TbNTR knockout, a similar
strategy was used, except the 5 and 3flanking regions were amplified (825 and
698 bp, respectively). Constructs were linearized (SacI/KpnI for the PAC vector or
MluI/KpnI for the BLA vector) then electroporated into T. brucei BSFs (43). The
vector used for overexpression was generated as follows: theTbNTRORF, lacking
the stop codon, was amplified from genomic DNA. The resultant fragment was
digested with HindIII/XbaI and cloned into the vector pLEW-tagC (D.H., unpub-
lisheddata).Theligationwasperformedsuchthatanepitope(9E10)derivedfrom
thehumanc-mycproteinwasaddedtotheCterminusofTbNTR.TheTbNTR-9E10
fusion was amplified, digested with HindIII/BglII and cloned into pRPaC-GFP (26),
such that the insert DNA replaced the GFP cassette. The AscI digested construct
was electroporated into T. brucei 2T1 cells. The vector used for localization was
generatedas follows:a255-bpDNAsequencecorrespondingtotheN-terminalof
TbNTR (amino acids 1–87) was amplified from genomic DNA and digested with
HindIII/XbaI. This was ligated into the HindIII/XbaI sites of vector pRPaC-GFP (26).
The cloning was carried out such that the gene coding for the GFP was inserted
in-frame at the 3 end of the TbNTR-derived DNA fragment. The AscI digested
construct was electroporated into T. brucei 2T1 parasites.
Localization.BSFtrypanosomesexpressingTbNTR-GFPweresuspendedat5106
cells ml1 in medium containing 100 nM MitoTracker Red (Molecular Probes) and
incubated at 37°C for 5 min. Cells were washed twice in PBS, fixed in 2%
paraformaldehyde/PBS, thenwashedagain inPBS.Aliquotsof thecell suspension
(105 cells) were then air-dried onto microscope slides. Parasite DNA was stained
with 200 pM DAPI (Sigma) in 50% glycerol/PBS and slides were viewed by using
a Zeiss LSM 510 confocal microscope.
Selection of Laboratory-Generated Nifurtimox-Resistant T. cruzi. T. cruzi epi-
mastigotes were seeded at 1105 ml1 in medium containing 10M nifurtimox.
After2monthsgrowthat27°C, theparasitesweresubcultured.Thiswasrepeated
every 3–4 weeks for a further 6 months before cloning by limited dilution.
Nifurtimox (10 M) was maintained throughout the selection.
Susceptibility Experiments. T. cruziepimastigotes were seeded at 5105 ml1 in
200 l of growth medium containing different concentrations of nifurtimox,
benznidazole, megazol, nitrofurazone, rimantidine, or G418. After incubation at
27°C for 2 days, 20l of Alamar blue (Biosource U.K. Ltd.) was added to each well
and the plates incubated for a further 10 days. Cell densities were determined by
monitoring the fluorescence of each culture using a Gemini Fluorescent Plate
reader (Molecular Devices) at an excitation wavelength of 530 nm, emission
wavelength of 585 nm, and a filter cutoff at 550 nm, and the drug concentration
that inhibits parasite growth by 50% (IC50) established. The reduction of Alamar
blue is proportional to the number of live cells, which was established after
production of a standard curve.
T.bruceiBSFparasiteswereseededat1103 ml1 in200lofgrowthmedium
containing different concentrations of nifurtimox, benznidazole, megazol, ni-
trofurazone, or melarsoprol. Where appropriate, induction was carried out by
adding tetracycline (1 g ml1). After incubation at 37°C for 3 days, 20 l of
Alamar blue was added to each well and the plates incubated for a further 16 h.
The cell density of each culture was determined as described above and the IC50
established.
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